New Results
A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2 neutralizing activity
View ORCID ProfileAdonis A. Rubio, Maria V. Filsinger Interrante, Benjamin N. Bell, Clayton L. Brown, Celia C. LaBranche, David C. Montefiori, Peter S. Kim
doi: https://doi.org/10.1101/2020.10.23.352526
Adonis A. Rubio
1Department of Biology, Stanford University School of Humanities & Sciences, Stanford, CA 94305, USA
Maria V. Filsinger Interrante
2Stanford Biophysics Program, Stanford University School of Medicine, Stanford, CA 94305, USA
3Stanford Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, 94305, USA
8Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA
Benjamin N. Bell
4Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA
8Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA
Clayton L. Brown
5Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
8Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA
Celia C. LaBranche
6Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
7Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
David C. Montefiori
6Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
7Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Peter S. Kim
5Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
8Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA
9Chan Zuckerberg Biohub, San Francisco, CA 94158, USA
Article usage
Posted October 24, 2020.
A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2 neutralizing activity
Adonis A. Rubio, Maria V. Filsinger Interrante, Benjamin N. Bell, Clayton L. Brown, Celia C. LaBranche, David C. Montefiori, Peter S. Kim
bioRxiv 2020.10.23.352526; doi: https://doi.org/10.1101/2020.10.23.352526
A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2 neutralizing activity
Adonis A. Rubio, Maria V. Filsinger Interrante, Benjamin N. Bell, Clayton L. Brown, Celia C. LaBranche, David C. Montefiori, Peter S. Kim
bioRxiv 2020.10.23.352526; doi: https://doi.org/10.1101/2020.10.23.352526
Subject Area
Subject Areas
- Biochemistry (11697)
- Bioengineering (8714)
- Bioinformatics (29110)
- Biophysics (14921)
- Cancer Biology (12045)
- Cell Biology (17347)
- Clinical Trials (138)
- Developmental Biology (9404)
- Ecology (14133)
- Epidemiology (2067)
- Evolutionary Biology (18260)
- Genetics (12214)
- Genomics (16758)
- Immunology (11838)
- Microbiology (27985)
- Molecular Biology (11543)
- Neuroscience (60766)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3224)
- Physiology (4934)
- Plant Biology (10379)
- Synthetic Biology (2876)
- Systems Biology (7331)
- Zoology (1640)